e18503 Background: Concurrent chemoradiation is standard of care for most patients with unresectable stage III A/B NSCLC but no standard chemotherapy regimen/schedule has been established. We conducted an experience to evaluate the efficacy and toxicity of a combination consisting of weekly docetaxel/cisplatin and radiotherapy in patients with unresectable stage III A/B NSCLC. Methods: Unresectable stage III A/B NSCLC pts with a good performance status (ECOG PS 0–1) were eligible. Patients with stage IIIB were chemonaive, while patients with stage IIIA were inoperable after a first line platinum-based chemotherapy. Treatment consisted of docetaxel 25 mg/m2 IV infusion followed by cisplatin 25 mg/m2 IV infusion was administered weekly during concurrent thoracic radiotherapy. Concurrent 3D-conformal RT thoracic radiation consisted of 45 Gy (1.8 Gy fractions 5 days/wk for first five weeks. Results: From 2006/01 to 2008/04, 16 pts were enrolled and all were evaluable for toxicity and response. Pt. characteristics: median age- 68 years (54–77), 80% males. Nine pts had stage IIIA (56%) and 7 patients had stage IIIB (44%).Histology subtypes included epidermoid (25%) and adenocarcinoma (75%). Radiologic response was seen in 11 patients (68%). Four patients had a stable disease (25%). Disease progression has occurred in 1 pt. Six patients undergone surgery after chemo-radiotherapy (37%). Four patients (25%) underwent a radical resection without residual mediastinal malignant disease. Toxicity was mild. Conclusions: Weekly docetaxel/cisplatin with concurrent 3D-conformal RT thoracic radiation plus is a well-tolerated out-patient regimen. and is feasible by multi-physicians collaboration group. No significant financial relationships to disclose.
Evaluate the outcome of pneumonectomy for stage III a-N2 NSCLC
